Novavax, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. Novavax is a biotechnology company whose sole commercial program is its COVID-19 vaccine; it is also developing influenza and COVID-19/influenza combination candidates and licenses its Matrix-M adjuvant.
Financial performance
Amounts are in millions of dollars except per-share data. Comparisons are with the corresponding 2022 period.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $187.0 | $734.6 | $692.4 | $1,624.5 |
| Product sales | $2.2 | $626.1 | $279.9 | $1,267.2 |
| Grant revenue | $164.9 | $106.3 | $389.4 | $313.3 |
| Cost of sales | $98.9 | $434.6 | $188.8 | $720.9 |
| Research and development | $106.2 | $304.3 | $572.8 | $977.4 |
| Selling, general and administrative | $107.5 | $122.9 | $313.7 | $327.0 |
| Operating loss | $(125.6) | $(127.2) | $(382.9) | $(400.9) |
| Net loss | $(130.8) | $(168.6) | $(366.7) | $(475.7) |
| Basic and diluted loss per share | $(1.26) | $(2.15) | $(3.94) | $(6.13) |
COVID-19 product sales fell sharply as dose sales declined. Grant revenue partly offset the reduction, including a $43.8 million cumulative revenue increase in Q3 tied to the U.S. government agreement. Cost of sales included inventory write-downs and losses on firm purchase commitments; revenue mix and these items make a simple product gross-margin comparison less informative.
- Cash flow: Operating cash use was $537.2 million for the first nine months, versus $298.1 million in 2022. Investing cash use was $49.7 million; financing cash use was $95.9 million, including repayment of $325.0 million of 2023 notes. Cash, cash equivalents and restricted cash declined by $682.5 million.
- Liquidity: September 30 cash, cash equivalents and restricted cash totaled $666.4 million, down from $1.35 billion at year-end 2022. Current assets were $1.01 billion and current liabilities $1.47 billion.
- Debt and equity: The company repaid its $325.0 million 3.75% convertible notes due 2023. Remaining convertible notes were $167.6 million net carrying value, due 2027, with a 5.00% coupon. Novavax issued shares through at-the-market sales and a private placement; weighted-average shares rose to 103.4 million in Q3 from 78.3 million.
Material changes and unusual items
- Nine-month revenue declined 57% year over year, primarily due to lower COVID-19 vaccine sales. Nine-month net loss narrowed, mainly reflecting lower cost of sales and R&D expense, partly offset by lower product revenue.
- Cost of sales included $121.6 million of inventory-related charges and firm purchase commitment losses for the first nine months, offset by $40.3 million of negotiated commitment recoveries. The company also recorded $10.1 million of restructuring-related asset impairment and $4.5 million of severance costs.
- A concurrent SK bioscience settlement and share placement produced a reported $79.2 million net gain on liability derecognition, recorded as reductions to R&D expense ($57.7 million) and cost of sales ($21.5 million). Novavax also agreed to pay SK $149.8 million, with $130.4 million paid in August.
- In May 2023, Novavax announced a restructuring that included workforce and manufacturing-footprint reductions. It expected about half the annual savings in 2023 and the full annual impact in 2024.
Outlook, risks and contingencies
- Going concern: Management states that substantial doubt exists about Novavax’s ability to continue as a going concern through one year after issuance of the financial statements. Its forecast estimates adequate capital but depends on uncertain vaccine revenue, execution of cost reductions and resolution of pending matters.
- Gavi arbitration: Gavi seeks repayment of advance payments; $696.4 million remained classified as a current liability at September 30. Novavax disputes the claim. The arbitration hearing is scheduled for July 2024, and an adverse outcome could require repayment of all or part of that amount.
- Commercial and contract risks: COVID-19 vaccine demand, adoption, delivery timing, regulatory authorizations and performance under advance purchase agreements are uncertain. A missed Canadian delivery condition could forfeit a further $174.8 million payment. The UK agreement also carries potential repayment exposure tied to specified recommendations; Novavax had repaid $112.5 million in April 2023 and disclosed possible additional repayment of up to $112.5 million.
- Manufacturing disputes and dependence: Novavax withheld a $34.3 million Fujifilm settlement installment and faces arbitration seeking payment. It relies on SIIPL/SLS for most finishing and on PCI Pharma Services for European finishing; disruptions could delay supply.
- Cost and capital plans: The company said it was preparing additional reductions intended to lower 2024 expenses by more than $300 million, including more than $200 million in R&D and SG&A reductions versus prior targets and more than $100 million in supply-network costs. It may seek further equity or debt financing, collaborations, asset sales or licensing arrangements; availability and terms are uncertain.
- Commercial outlook: Management estimated U.S. 2023–2024 season demand of 30–50 million COVID-19 vaccine doses. The updated vaccine received U.S. EUA and European Commission approval in October 2023, after quarter-end. Management expected a Phase 3 CIC trial to begin in the second half of 2024, with potential accelerated approval and launch as early as 2026; these are forward-looking targets.
- Other matters include securities and derivative litigation, whose financial impact the company says is not estimable, and potential costs or repayment obligations under customer agreements. The filing reports disclosure controls were effective at the reasonable-assurance level.
Investor verification priorities
- Track vaccine sales, actual market adoption and delivery performance against 2023–2024 expectations and advance purchase agreement commitments.
- Monitor cash burn, available financing, restructuring execution and whether the stated going-concern uncertainties change.
- Follow the Gavi arbitration and the accounting and liquidity implications of the $696.4 million disputed advance payment.
- Confirm receipt of the contingent Canadian payment and progress toward required manufacturing approval and the Canada memorandum of understanding.
- Review inventory obsolescence, firm purchase commitment exposure, manufacturing-settlement disputes and any further charges or cash obligations.
- Assess dilution from equity issuance and progress, regulatory milestones and funding needs for the CIC, influenza and other programs.